Lewis Bender

The Non-Opioid Pain Therapeutics Summit provides a dedicated platform to harness the current momentum in the pain space. Attendees will be learning from companies with approvals such as Tonix and Vertex, exploring late-stage strategies from innovators like Latigo and Algiax, and uncovering discovery breakthroughs from Nocion and Axonis. Join discovery, preclinical, translational and clinical industry-based experts driving the future of non-opioid pain therapies.

By Lewis H. Bender, CEO, Intensity Therapeutics While breast cancer (BC) rates in younger women are rising, so is the number of women with a highly aggressive form of the disease, known as triple negative. In this BC subtype, women test negative for three surface proteins (progesterone, estrogen, and Her2), which limits the number of medicines that can treat the patient’s cancer.

clear search menu Search for Articles: You can use * to search for partial matches. Logical OperatorOperator Submit to this Journal Review for this Journal Edit a Special Issue Article Menu /ajax/scifeed/subscribe Need Help? Support Find support for a specific problem on the support section of our website. Get Support Feedback Please let us know what you think of our products and services. Give Feedback Information Our dedicated information section provides allows you to learn more about MDPI.